Vividion Therapeutics IPO

Vividion Therapeutics is a biotechnology company focused on transforming the future of human health through the creation of highly selective small molecule medicines that drug traditionally inaccessible targets.

Register for Details

For more details on financing and valuation for Vividion Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Vividion Therapeutics Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
2/24/2021 Series C $135MM raised $XXX.XX $XXX.XX
4/30/2019 Series B $82MM raised $XXX.XX $XXX.XX
2/2/2017 Series A-2 and A-3 $46.3MM raised $XXX.XX $XXX.XX
3/31/2016 Series A $4.53MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data

Learn more about Vividion Therapeutics

Forge green plus iconForge green minus icon

What is Vividion Therapeutics funding to date?

Vividion Therapeutics has raised $267.82MM to date.
Forge green plus iconForge green minus icon

When was Vividion Therapeutics founded?

Vividion Therapeutics was founded in 2013.
Updated on: Jun 12, 2022


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.